The Liverpool, UK-headquartered firm, which makes powder containment and aseptic transfer valves for powder, granular and semi-solid drug ingredients, is adding an office in San Francisco, California.
A ChargePoint spokesperson told in-PharmaTechnologist the decision to expand its US presence - ChargePoint established a New Jersey sales office in 2009 – responds to an increased market demand in North America.
“ChargePoint has had a growing client base in the US for a number of years so is not new to the market. Due to this demand, we have taken the decision to establish a more localised presence on the West Coast.”
“Clearly there is a growing biotech market in the US, supported by a positive investor climate. These products require sterile containment during manufacturing and this demand forms part of our reason for continuing to invest in the US market,” the spokesperson said.
According to ChargePoint, a growing demand for cancer drugs also influenced the decision.
“More generally, global demand and growth in the oncology market and an increase in conventional drug manufacturing using high potency APIs is also driving demand for high-containment manufacturing capabilities and this trend is certainly notable in the US,” said the spokesperson.
The company said the expansion will create jobs in the US and contribute to the firm’s objective of doubling its workforce by 2020.